Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Matthew Seymour, MD: A Clinical Trialist’s Perspective

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Advertisement

Advertisement




Apr
24
Today In Oncology
Long-Term Immunotherapy for Alveolar Soft Part Sarcoma
AMA Data Show Nearly 50 Percent of Surveyed Oncologists Reported Burnout in 2025
Unique Phase I NSCLC Trial Sites Decreasing in United States
Overall Survival With Addition of Relacorilant to Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer
Tislelizumab With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo